R J Bio-Tech Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 9.47 Cr
- Company Age 19 Year, 1 Month
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 27.15 Cr
- Satisfied Charges ₹ 15.05 Cr
- Revenue Growth 31.68%
- Profit Growth 63.95%
- Ebitda 52.80%
- Net Worth -19.47%
- Total Assets -8.52%
About R J Bio-Tech
Company Details
-
Location
Aurangabad, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
L24234MH2005PLC158420
-
Company No.
158420
-
Stock Symbol
BSE : 536456
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
28 Dec 2005
-
Date of AGM
30 Sep 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Listed
-
ROC Code
Roc Mumbai
Industry
What products or services does R J Bio-Tech Limited offer?
R J Bio-Tech Limited offers a wide range of products and services, including Seeds, Hybrid Seeds, Fruit Seeds, Hybrid Watermelon Seeds, Hybrid Cotton Seed, Grain Seed, Paddy Seeds, Hybrid Vegetable Seeds, Hybrid Brinjal Seed, Fresh Vegetables.
Who are the key members and board of directors at R J Bio-Tech?
Executive Team (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Yogesh Shelke | CFO | 01-Jul-2020 | Current |
Ruchita Zalte | Company Secretary | 11-Jan-2022 | Current |
Board Members (4)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Balram Yerme | Director | 05-Jan-2019 | Current |
Aditi Joshi | Director | 14-Jun-2019 | Current |
Harshwardhan Joshi | Director | 14-Jun-2019 | Current |
Prashant Shukla | Director | 05-Mar-2021 | Current |
Financial Performance of R J Bio-Tech.
R J Bio-Tech Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 31.68% increase. The company also saw a substantial improvement in profitability, with a 63.95% increase in profit. The company's net worth observed a substantial decline by a decrease of 19.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of R J Bio-Tech?
In 2020, R J Bio-Tech had a promoter holding of 60.29% and a public holding of 39.71%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹27.15 Cr
₹15.05 Cr
Charges Breakdown by Lending Institutions
- State Bank Of India : 27.15 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
09 Jan 2012 | State Bank Of India | ₹27.15 Cr | Open |
29 Nov 2008 | Idbi Bank Limited | ₹15.05 Cr | Satisfied |
How Many Employees Work at R J Bio-Tech?
R J Bio-Tech has a workforce of 2 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of R J Bio-Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped R J Bio-Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.